Eli Lilly joins SNM imaging network

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 5
Volume 19
Issue 5

Eli Lilly has joined SNM’s Clinical Trials Network, a collaborative effort designed to address the need for validated imaging biomarkers for streamlining the development and registration of investigational therapeutics.

Eli Lilly has joined SNM's Clinical Trials Network, a collaborative effort designed to address the need for validated imaging biomarkers for streamlining the development and registration of investigational therapeutics.

The network also applies for and holds FDA new drug applications that will be available for cross-reference in multicenter clinical trials of imaging agents to assess response to treatment or to stratify patients for enrollment in clinical trials. "Eli Lilly seeks to improve patient outcomes by accelerating our therapeutic pipeline by using molecular imaging," said Johannes Tauscher, MD, a medical fellow and head of the translational imaging group at the company.

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Greater cancer treatment longevity enables oncologists the ability to form more impactful relationships with their patients.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content